BusinessUPDATE - FibroGen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic CancerBy Nasdaq OMXMar 1, 2018, 6:45 PM UTC
BusinessFibrogen Granted Fast Track Designation by U.S. FDA for Pamrevlumab Treatment of Patients with Locally Advanced Unresectable Pancreatic CancerBy Nasdaq OMXMar 1, 2018, 12:03 PM UTC
BusinessFibroGen Reports Fourth Quarter and Full Year 2017 Financial ResultsBy Nasdaq OMXFeb 27, 2018, 9:11 PM UTC
BusinessFibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017By Nasdaq OMXOct 31, 2017, 12:00 AM UTC
BusinessFibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)By Nasdaq OMXOct 18, 2017, 11:01 AM UTC
BusinessFibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017By Nasdaq OMXSep 5, 2017, 8:06 PM UTC
BusinessFibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary FibrosisBy Nasdaq OMXAug 7, 2017, 8:50 PM UTC
